跳到正文
营养与代谢随机对照试验3 分钟阅读

2型糖尿病:空腹血糖日间波动大,与严重低血糖和死亡相关

MoveVitals 编辑部 · 研究发表 · 解读更新

原文:Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). · Diabetologia · 2017 · 论文原文 ↗

先看重点

在胰岛素试验DEVOTE的二次分析中,空腹自测血糖的日间变异越大,校正前严重低血糖(HR 4.11,95%置信区间3.15至5.35)和全因死亡(HR 1.58,95%置信区间1.23至2.03)风险越高。这两项关联在校正后仍成立,但与主要心血管不良事件的关联不再成立,且该设计只能说明相关性。

证据类型

随机对照试验

解读依据

公开摘要

阅读重点

对照与不确定性

研究在问什么

血糖逐日起伏不定,除平均水平之外可能还有独立风险。作者利用DEVOTE试验(在心血管高风险的2型糖尿病患者中比较德谷胰岛素与甘精胰岛素U100)来检验:空腹血糖的日间变异是否与严重低血糖和心血管结局有关。

研究了谁,如何研究

对DEVOTE试验做二次分析,该试验为双盲、随机、事件驱动、以达标为目标的试验。变异定义为早餐前自测血糖(SMBG)的标准差:每月只取与研究中心联系前记录的3次读数,取对数后求方差,对各月方差取平均再开平方。用Cox比例风险模型在合并后的试验人群中分析其与严重低血糖、主要心血管不良事件(MACE)及全因死亡的关联,并做了校正基线特征和最近一次HbA1c的敏感性分析。摘要没有给出参与者人数。

主要发现

以下为作者报告的结果。数字须连同人群和不确定性一起阅读。

  1. 1
    校正前,变异越大,严重低血糖(HR 4.11,95%置信区间3.15至5.35)、MACE(HR 1.36,95%置信区间1.12至1.65)和全因死亡(HR 1.58,95%置信区间1.23至2.03)的风险越高。
  2. 2
    患者的变异指标增加一倍,对应严重低血糖风险为2.7倍,MACE为1.2倍,全因死亡为1.4倍。
  3. 3
    与严重低血糖和全因死亡的关联在校正后仍然存在;摘要没有给出校正后的具体数值。
  4. 4
    与MACE的关联在校正基线特征及基线HbA1c(HR 1.19,95%置信区间0.96至1.47)或最近一次HbA1c(HR 1.21,95%置信区间0.98至1.49)后不再成立。

局限与不确定性

  1. 1
    这是随机试验内的二次观察性分析,不能说明降低变异就能降低风险。
  2. 2
    变异仅来自每月3次空腹自测读数,可能存在较大噪声。
  3. 3
    参与者为使用基础胰岛素、心血管高风险的2型糖尿病患者,结果未必适用于风险较低或使用其他治疗的人。
  4. 4
    极端血糖或健康状况较差可能同时造成读数不稳和事件发生,校正未必能完全排除这一点。

对日常健康的启示

在这个高风险试验人群中,空腹血糖逐日大幅波动与更多严重低血糖和死亡同时出现。因此平稳的读数值得与医疗团队讨论,但研究并未说明如何做到。不要自行调整胰岛素剂量。

如何联系自己的数据

如果你测空腹血糖或佩戴连续血糖监测仪,可以看清晨读数在不同天之间的离散程度,使用同一台血糖仪或传感器,并保持测量时间一致。把规律反映给医生,而不是对单次读数做出反应。

如何理解这类证据

随机分组有助于因果推断,仍须检查分配、盲法、失访、随访时间和具体对照;标为随机试验不自动意味着高确定性。

作者的结构化摘要 English

以下英文摘要按记录的开放许可转载,属于作者原始材料,不是 MoveVitals 的解读。上方已提供研究解读,分别说明作者结果与本站解释;重要结论可直接核对原文。

Aims/hypothesis

The Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE) was a double-blind, randomised, event-driven, treat-to-target prospective trial comparing the cardiovascular safety of insulin degludec with that of insulin glargine U100 (100 units/ml) in patients with type 2 diabetes at high risk of cardiovascular events. This paper reports a secondary analysis investigating associations of day-to-day fasting glycaemic variability (pre-breakfast self-measured blood glucose [SMBG]) with severe hypoglycaemia and cardiovascular outcomes.

Methods

In DEVOTE, patients with type 2 diabetes were randomised to receive insulin degludec or insulin glargine U100 once daily. The primary outcome was the first occurrence of an adjudicated major adverse cardiovascular event (MACE). Adjudicated severe hypoglycaemia was the pre-specified secondary outcome. In this article, day-to-day fasting glycaemic variability was based on the standard deviation of the pre-breakfast SMBG measurements. The variability measure was calculated as follows. Each month, only the three pre-breakfast SMBG measurements recorded before contact with the site were used to determine a day-to-day fasting glycaemic variability measure for each patient. For each patient, the variance of the three log-transformed pre-breakfast SMBG measurements each month was determined. The standard deviation was determined as the square root of the mean of these monthly variances and was defined as day-to-day fasting glycaemic variability. The associations between day-to-day fasting glycaemic variability and severe hypoglycaemia, MACE and all-cause mortality were analysed for the pooled trial population with Cox proportional hazards models. Several sensitivity analyses were conducted, including adjustments for baseline characteristics and most recent HbA_(1c).

Results

Day-to-day fasting glycaemic variability was significantly associated with severe hypoglycaemia (HR 4.11, 95% CI 3.15, 5.35), MACE (HR 1.36, 95% CI 1.12, 1.65) and all-cause mortality (HR 1.58, 95% CI 1.23, 2.03) before adjustments. The increased risks of severe hypoglycaemia, MACE and all-cause mortality translate into 2.7-, 1.2- and 1.4-fold risk, respectively, when a patient's day-to-day fasting glycaemic variability measure is doubled. The significant relationships of day-to-day fasting glycaemic variability with severe hypoglycaemia and all-cause mortality were maintained after adjustments. However, the significant association with MACE was not maintained following adjustment for baseline characteristics with either baseline HbA_(1c) (HR 1.19, 95% CI 0.96, 1.47) or the most recent HbA_(1c) measurement throughout the trial (HR 1.21, 95% CI 0.98, 1.49).

Conclusions/interpretation

Higher day-to-day fasting glycaemic variability is associated with increased risks of severe hypoglycaemia and all-cause mortality.

Trial registration

ClinicalTrials.gov NCT01959529.

来源与署名

Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2).

Zinman B, Marso SP, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Lange M, Brown-Frandsen K, Moses A, Ocampo Francisco AM, Barner Lekdorf J, Kvist K, Buse JB, DEVOTE Study Group.

Diabetologia · 2017-09-15

DOI: 10.1007/s00125-017-4423-z ↗PubMed · 28913575 ↗Europe PMC · 记录的开放许可: cc by ↗

摘要版权归原作者,依据来源记录的开放许可转载。中文译文辅助阅读,英文摘要用于核对术语与具体数值;本站的方法学解释与作者结论分别呈现。

MoveVitals 编辑解读 · 健康教育内容 · 未记录个人临床审阅

来源核验日期 2026-11-01

实用健康指南

放在一起读

·随机试验荟萃分析

更早的进食窗口与更大的体重和胰岛素获益相关,优于晚间进食

汇总41项随机对照试验(2287名参与者,干预时间中位数8周)发现,限时进食比日常饮食体重低2.15 kg(95%置信区间−2.56至−1.74),而早吃比晚吃体重多降1.15 kg(95%置信区间−1.86至−0.45)。多数试验较短,只有6个研究组检验了早间进食,结局是身体和血液指标,不是心脏病发作或死亡。

BMJ Medicine

重点论文精讲阅读论文 →
·随机对照试验

限热量饮食再加上午8点至下午4点进食窗口,1年减重无明显额外优势

139名肥胖患者都按限制热量的饮食进食,其中一组再加上上午8:00至下午4:00的进食窗口,12个月平均体重变化为−8.0 kg,单纯限热量组为−6.3 kg。净差值−1.8 kg(95%置信区间−4.0至0.4;P=0.11)无统计学意义,该区间既不能排除窗口确有获益,也不能排除毫无作用。

The New England Journal of Medicine

重点论文精讲阅读论文 →
·随机对照试验

20人住院试验:超加工饮食让人每天多摄入508 kcal并增重

20名成年人在医院研究病房住了28天,两种菜单各吃2周、想吃多少吃多少:超加工菜单让他们每天多摄入508 kcal(±106,标准误,P=0.0001),体重增加0.9 kg;未加工菜单则让体重减轻0.9 kg。样本小、周期短、食物全程由研究方提供,既不能说明日常生活中的长期结果,也无法确定是食物的哪种特点导致多吃。

Cell Metabolism

重点论文精讲阅读论文 →
·随机对照试验

地中海饮食加橄榄油或坚果与心血管事件减少相关(更正后的试验)

在7447名55至80岁、心血管风险较高的西班牙成年人中,被分到加特级初榨橄榄油(风险比0.69,95%置信区间0.53至0.91)或加坚果(风险比0.72,0.54至0.95)的地中海饮食组,发生主要心血管事件的风险低于被告知减少脂肪的对照组。试验存在随机化失误,2013年的报告已撤回并重新估算,证据有力但并不完美。

The New England Journal of Medicine

重点论文精讲阅读论文 →
营养与代谢 →